GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » FOXO Technologies Inc (AMEX:FOXO) » Definitions » ROCE %

FOXO Technologies (FOXO Technologies) ROCE % : 0.00% (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is FOXO Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. FOXO Technologies's annualized ROCE % for the quarter that ended in Sep. 2023 was 0.00%.


FOXO Technologies ROCE % Historical Data

The historical data trend for FOXO Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FOXO Technologies ROCE % Chart

FOXO Technologies Annual Data
Trend Dec20 Dec21 Dec22
ROCE %
-99.09 -2,448.08 -825.18

FOXO Technologies Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5,606.08 -209.17 -199.15 - -

FOXO Technologies ROCE % Calculation

FOXO Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-93.815/( ( (30.304 - 36.061) + (35.408 - 6.913) )/ 2 )
=-93.815/( (-5.757+28.495)/ 2 )
=-93.815/11.369
=-825.18 %

FOXO Technologies's ROCE % of for the quarter that ended in Sep. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-14.048/( ( (4.047 - 10.158) + (3.131 - 13.516) )/ 2 )
=-14.048/( ( -6.111 + -10.385 )/ 2 )
=-14.048/-8.248
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FOXO Technologies  (AMEX:FOXO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


FOXO Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of FOXO Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


FOXO Technologies (FOXO Technologies) Business Description

Traded in Other Exchanges
N/A
Address
729 Washington Avenue N, Suite 600, Minneapolis, MN, USA, 55401
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging.
Executives
Martin Christopher Ward officer: Interim CFO CHALKSTREAM, KINGS SOMBORNE, STOCKBRIDGE X0 S020 6NZ
Mark Brian White director, officer: Interim CEO IMMEUBLE MILA, CHAMPERY V8 1874
Dowling Vincent J. Jr 10 percent owner 54 LEDYARD, WEST HARTFORD CT 06117
Gwg Holdings, Inc. 10 percent owner 325 N. ST. PAUL STREET, SUITE 2650, DALLAS TX 75201
Taylor Fay officer: Chief Operating Officer 729 N. WASHINGTON AVE, SUITE 600, MINNEAPOLIS MN 55401
Jon Sabes director, 10 percent owner, officer: CEO, Chairman 701 NORTH THIRD STREET, MINNEAPOLIS MN 55401
Bret Barnes director 220 SOUTH SIXTH STREET, MINNEAPOLIS MN 55402
Brian Chen officer: Chief Science Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Erin Sharoni officer: Chief Product Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Michael Will officer: General Counsel 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Tyler Danielson officer: Chief Technology Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Murdoc Khaleghi director 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Robert Potashnick officer: Chief Financial Officer 220 SOUTH SIXTH STREET, SUITE 1200, MINNEAPOLIS MN 55402
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul Britton Newhouse director ONE CITY CENTRE, 1021 MAIN STREET SUITE 1960, HOUSTON TX 77002

FOXO Technologies (FOXO Technologies) Headlines